News & Media

Take a closer look at what we’re doing across Teva worldwide

Our latest news

Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin Expansion

Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.

Teva to Discontinue Phase 2 TOPAS-MSA Study of emrusolmin (TEV-‘286) Following Interim Futility Analysis

Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline

UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease

Teva to Host R&D Day on Wednesday, November 11 in New York City

Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia

Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients

Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome

TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness
See all news items

Discover the world of Teva

Follow our latest feature stories with news and views from across our global organization

Discover more

Media Resources

at the office

Media Inquiries

Contact our corporate communications.
Learn more

Media Kit

Files and resources for media use only
Download Teva Media Kit

Financial Reports

View Teva financial news on our global website.
Learn more

Connect with us

Teva Social Media Guidelines.
Learn more